Articles by Jim Miller - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jim Miller

Cautious Hopefullness: Contract Services Industry's Fortunes Unclear for 2010

As facility closures and layoffs continue, CRO and CMO executives are hoping for a better year, despite few positive signs.
Feb 1, 2010

As facility closures and layoffs continue, CRO and CMO executives are hoping for a better year, despite few positive signs.

CDMOs Benefit from the Growing Biologics Market

A new analysis highlights growth opportunities and challenges for contract development and manufacturing organizations.
Dec 1, 2009

A new analysis highlights growth opportunities and challenges for contract development and manufacturing organizations.

Building a Turnkey Manufacturing Solution

Lonza's bid for Patheon makes the contract manufacturing industry re-examine the one-stop manufacturer model.
Oct 1, 2009

Lonza's bid for Patheon makes the contract manufacturing industry re-examine the one-stop manufacturer model.

Waiting for Godot: Will Venture Funding Return?

Contract research, development, and manufacturing organizations betting on a comeback in venture capital financing will have a long wait.
Aug 1, 2009

Contract research, development, and manufacturing organizations betting on a comeback in venture capital financing will have a long wait.

UK Service Providers Look to the New World

UK-based CMOs seek opportunities in new markets.
Jun 1, 2009

UK-based CMOs seek opportunities in new markets.

Declining Market Demand Intensifies Competition

The current competitive environment is forcing service providers to evaluate their business models and focus on value and performance.
May 1, 2009

The current competitive environment is forcing service providers to evaluate their business models and focus on value and performance.

Less Venture Capital Means Less Work for CROs

As financing for early-stage companies gets tighter, small CROs will find fewer new business opportunities
Feb 1, 2009

What the current lack of venture capital means for the CRO market.

Biomanufacturing Capacity Quandary

The outlook for cell culture capacity is highly variable, but contract manufacturing capacity could be tight.
Nov 1, 2008

There could be a serious glut of commercial scale mammalian cell culture capacity over the next five years. Then again, there could be a significant shortage. It all depends on how things develop in expression technology, the new product pipeline, and corporate strategies.

The Art of the Deal

CMOs should recognize that strategic outsourcing relationships must be based on more than just capacity.
Sep 1, 2008

Risk mitigation should be a key aspect of any contract manufacturing organization's business strategy.

ADVERTISEMENT

ADVERTISEMENT

Click here